High expression of ATAD2 and MYC signaling were also associated with increased risk of cancer progression (p = 0.003 and p = 0.015, respectively), cancer-specific death (p = 0.004 and p = 0.001) (Figures 2c–d), and other poor-prognosis features. Here, ATAD2 is linked to cancer.